Merck Sharp + Dohme Corp.

Merck Sharpe & Dohme Corp.

Paul John Whiting

Beatrice Le Bourdelles

Karen Louise Hadingham

Jose Luis Castro Pineiro

Ruth McKernan

Timothy Peter Bonnert

George McAllister

Janice Ann Myers

Peter Baxter Wingrove

The present invention relates to the cloning of novel cDNA sequences encoding the &#x3b1;and &#x3b4; receptor subunits of the human GABAreceptor; to stably co-transfected eukaryotic cell lines capable of expressing a human GABAreceptor, which receptor comprises at least one of the novel &#x3b1;and &#x3b4; receptor subunits; and to the use of such cell lines in screening for and designing medicaments which act upon the human GAGAreceptor.

Delta subunit of human GABAA receptor

This invention concerns the cloning of a novel cDNA sequence encoding a particular subunit of the human GABA receptor. In addition, the invention relates to a stable cell line capable of expressing said cDNA and to the use of the cell line in a screening technique for the design and development of subtype-specific medicaments.

Human theta subunit of the GABAa receptor

The present invention provides nucleotide sequences encoding the &agr; and &dgr; subunits of the human GABA receptor, preparations of &agr; and &dgr; receptor subunit proteins, preparations of receptors including &agr; or &dgr; polypeptides, expression vectors including the nucleotide sequences, stably co-transfected eukaryotic cells and methods of their preparation and methods of screening for and designing medicaments which act upon the GABA receptor.

Human &agr;4 receptor subunit of the GABA-A receptor

A class of substituted or 7,8-ring fused 1,2,4-triazolo&lsqb;4,3-b&rsqb;pyridazine derivatives, possessing an optionally substituted cycloalkyl, phenyl or heteroaryl substituent at the 3-position and a substituted alkoxy moiety at the 6-position, are selective ligands for GABA,receptors, in particular having high affinity for the &agr;2 and/or &agr;3 subunit thereof, and are accordingly of benefit in the treatment and/or prevention of psychotic disorders including schizophrenia.

Antipsychotic use of triazolo-pyridazine derivatives

Human NMDA R2A receptor subunit and isoforms of the human NMDA-R1

The present invention relates to a stably co-transfected eukaryotic cell line capable of expressing a GABA-A receptor, particularly a human GABA-A receptor, which receptor comprises at least one alpha, one beta and one gamma subunit; to the cloning of novel cDNA sequences encoding the .alpha.-2, .alpha.-3, .alpha.-5, .alpha.-6 and .beta.-2 subunits of the human GABA-A receptor; and to the use of the cell line in designing and developing GABA-A receptor subtype-selective medicaments.

Growing community of inventors

Stansted Mountfitchet, United Kingdom

Paul John Whiting